Evidence map›Paper›PMID 36683028›Full record

ArticleSubstance abuse treatment, prevention, and policy2023

Tobacco harm reduction in Afghanistan: a recipe for improving smokers' health.

Attaullah Ahmadi, Ali Rahimi, Mohammad Faisal Wardak, Hamidullah Ahmadi, Don Eliseo Lucero-Prisno

Abstract readLetter
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Attaullah AhmadiÉcole des Hautes Études en Santé Publique, Paris, France.
Ali RahimiMedical Faculty, Herat University, Students Street, Herat, 3001, Afghanistan. dr.rahimi@outlook.com.
Mohammad Faisal WardakMedical Faculty, Herat University, Students Street, Herat, 3001, Afghanistan.
Hamidullah AhmadiAmerican University of Afghanistan, Kabul, Afghanistan.
Don Eliseo Lucero-PrisnoFaculty of Management and Development Studies, University of the Philippines Open University, Los Banos, Laguna, Philippines.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobacco Harm Reduction (THR) offers a promising approach to addressing the significant burden of smoking in Afghanistan. Over three million Afghans smoke daily, making it a leading cause of preventable deaths in the country. While the previous Afghan government implemented various tobacco cessation policies and strategies, these measures were only partially effective in reducing the number of smokers or smoking-related deaths. In 2021, community-based initiatives in Kabul and Herat started advocating for Tobacco Harm Reduction (THR) as a novel, realistic, and practical approach proven to promote smoking abstinence and minimize tobacco harm. However, implementing THR strategies in Afghanistan faces numerous challenges, including a lack of governmental support, funding issues, unfavorable market conditions, the high cost-effectiveness of THR products, and misconceptions about these products. To effectively promote THR in Afghanistan and overcome these challenges, it will be necessary to implement THR policies that support THR products for smokers, regulate the market for these products, produce them locally with healthcare professional oversight, conduct more engaging advocacy campaigns, and secure domestic sponsors.

Indexed as

Smoking CessationAfghanistanHarm ReductionHumansNicotianaSmokersAfghanistanE-cigarettesHarm reductionSmoking cessationTobaccoTobacco harm reduction

Identifiers

PMID36683028
PMCPMC9867861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.